Acelyrin (SLRN) News Today $2.60 +0.43 (+19.82%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$2.60 +0.00 (+0.19%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Acelyrin Stock Jumps on Concentra Acquisition InterestFebruary 21 at 4:23 PM | marketwatch.comAcelyrin Stock Jumps on Concentra Acquisition InterestFebruary 21 at 4:23 PM | marketwatch.comAcelyrin confirms unsolicited indication of interest from Concentra BiosciencesFebruary 21 at 1:46 AM | markets.businessinsider.comAcelyrin jumps 11% on acquisition offer from Concentra BiosciencesFebruary 21 at 1:46 AM | msn.comACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra BiosciencesFebruary 20 at 9:00 PM | globenewswire.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Acelyrin, Inc. BuyoutFebruary 12, 2025 | markets.businessinsider.comSLRN stock touches 52-week low at $1.85 amid market challengesFebruary 11, 2025 | msn.comAlumis price target lowered to $26 from $32 at OppenheimerFebruary 10, 2025 | markets.businessinsider.comPiper Sandler Sticks to Their Buy Rating for ACELYRIN, INC. (SLRN)February 8, 2025 | markets.businessinsider.comACELYRIN, INC. (SLRN) Receives a Buy from Wells FargoFebruary 8, 2025 | markets.businessinsider.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.February 7, 2025 | prnewswire.comAcelyrin Inc trading halted, news pendingFebruary 7, 2025 | markets.businessinsider.comSLRN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ACELYRIN, Inc. Is Fair to ShareholdersFebruary 6, 2025 | businesswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Acelyrin, Inc. - SLRNFebruary 6, 2025 | prnewswire.comAlumis and ACELYRIN Agree to Merge in All-Stock DealFebruary 6, 2025 | marketwatch.comAlumis and ACELYRIN announce merger in all-stock dealFebruary 6, 2025 | msn.comAlumis, Acelyrin to merge in all-stock transactionFebruary 6, 2025 | markets.businessinsider.comShareholder Alert: Ademi & Fruchter LLP investigates whether ACELYRIN, INC. is obtaining a Fair Price for its Public ShareholdersFebruary 6, 2025 | businesswire.comAlumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated DiseasesFebruary 6, 2025 | globenewswire.comSLRN stock touches 52-week low at $1.9 amid market challengesJanuary 28, 2025 | msn.comJPMorgan Chase & Co. Cuts Stake in Acelyrin, Inc. (NASDAQ:SLRN)JPMorgan Chase & Co. lowered its stake in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 67.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 850,661 shares of the company's stock after selling 1,747,642 shares during the quarter. JPJanuary 18, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for Acelyrin Q1 Earnings?Acelyrin, Inc. (NASDAQ:SLRN - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Acelyrin in a research note issued on Tuesday, January 7th. HC Wainwright analyst E. Bodnar anticipates that the company will earn ($0.44) per sJanuary 9, 2025 | marketbeat.comCautious Hold Rating for ACELYRIN, INC. Amid Uncertainties in Lonigutamab’s Efficacy and DosingJanuary 8, 2025 | markets.businessinsider.comACELYRIN, INC. (SLRN) Receives a Buy from TD CowenJanuary 7, 2025 | markets.businessinsider.comAcelyrin price target lowered to $3 from $6 at CitiJanuary 7, 2025 | markets.businessinsider.comCitigroup Has Lowered Expectations for Acelyrin (NASDAQ:SLRN) Stock PriceCitigroup cut their price target on shares of Acelyrin from $6.00 to $3.00 and set a "neutral" rating on the stock in a research note on Tuesday.January 7, 2025 | marketbeat.comAcelyrin falls after updating mid-stage trial data for eye disease drugJanuary 7, 2025 | msn.comAcelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionJanuary 7, 2025 | benzinga.comAcelyrin (NASDAQ:SLRN) Price Target Cut to $6.00 by Analysts at HC WainwrightHC Wainwright reduced their price target on shares of Acelyrin from $8.00 to $6.00 and set a "neutral" rating on the stock in a research report on Tuesday.January 7, 2025 | marketbeat.comAcelyrin announces additional lonigutamab data, design for LONGITUDE programJanuary 7, 2025 | markets.businessinsider.comACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye DiseaseJanuary 6, 2025 | globenewswire.comAcelyrin spikes on upcoming mid-stage data update on eye disease drugJanuary 4, 2025 | msn.comWhat's Going On With ACELYRIN Shares Friday?January 3, 2025 | benzinga.comAcelyrin, Inc. (NASDAQ:SLRN) Shares Purchased by Geode Capital Management LLCGeode Capital Management LLC grew its holdings in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 30.8% in the third quarter, according to its most recent filing with the SEC. The firm owned 1,651,614 shares of the company's stock after acquiring an additional 388,631 shares during the quarJanuary 3, 2025 | marketbeat.comACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous LonigutamabJanuary 2, 2025 | globenewswire.comWhy Is Acelyrin, Inc. (SLRN) Among the Best Biotech Penny Stocks to Invest in Now?December 30, 2024 | msn.comHold Rating Maintained for ACELYRIN, INC. Amidst Izokibep Study Setback and Revised Sales ProjectionsDecember 19, 2024 | markets.businessinsider.comFmr LLC Sells 4,596,424 Shares of Acelyrin, Inc. (NASDAQ:SLRN)Fmr LLC lowered its holdings in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 97.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 117,748 shares of the company's stock after sellingDecember 19, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Acquires 273,604 Shares of Acelyrin, Inc. (NASDAQ:SLRN)Charles Schwab Investment Management Inc. grew its holdings in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 81.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 609,678 shares of the company's stock after purchaDecember 15, 2024 | marketbeat.comAcelyrin Finance Chief Gil Labrucherie to ExitDecember 12, 2024 | marketwatch.comAcelyrin Shares Fall After Halting Development of Eye Disease TreatmentDecember 11, 2024 | marketwatch.comAcelyrin announces izokibep trial did not meet primary endpointDecember 11, 2024 | markets.businessinsider.comAcelyrin (NASDAQ:SLRN) Stock Quotes, Forecast and News SummaryDecember 11, 2024 | benzinga.comAcelyrin (NASDAQ:SLRN) Receives "Neutral" Rating from HC WainwrightHC Wainwright reaffirmed a "neutral" rating and issued a $8.00 price objective on shares of Acelyrin in a research note on Wednesday.December 11, 2024 | marketbeat.comPoint72 Asset Management L.P. Has $1.23 Million Stock Holdings in Acelyrin, Inc. (NASDAQ:SLRN)Point72 Asset Management L.P. lifted its position in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 566.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 250,300 shares of the company's stoDecember 11, 2024 | marketbeat.comACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of UveitisDecember 10, 2024 | globenewswire.comAcelyrin: Abandoned Programs Do Not Give ConfidenceDecember 9, 2024 | seekingalpha.comPolar Asset Management Partners Inc. Trims Stock Position in Acelyrin, Inc. (NASDAQ:SLRN)Polar Asset Management Partners Inc. decreased its stake in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 67.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 71,700 shares of the company's stockDecember 7, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Sells 153,465 Shares of Acelyrin, Inc. (NASDAQ:SLRN)Jacobs Levy Equity Management Inc. trimmed its holdings in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 10.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,326,391 shares of the company's stock afteDecember 6, 2024 | marketbeat.com364,000 Shares in Acelyrin, Inc. (NASDAQ:SLRN) Acquired by Acuta Capital Partners LLCAcuta Capital Partners LLC purchased a new stake in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 364,000 shares of the company's stock, valued at approximatelNovember 28, 2024 | marketbeat.com Get Acelyrin News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter. Email Address SLRN Media Mentions By Week SLRN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLRN News Sentiment▼0.180.60▲Average Medical News Sentiment SLRN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLRN Articles This Week▼53▲SLRN Articles Average Week Get Acelyrin News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DNA News IMNM News AVDL News CVAC News CDMO News NUVB News PRTA News CRON News GHRS News BCAX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLRN) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acelyrin, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acelyrin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
